Lean Metabolic-Associated Fatty Liver Disease

Area of Science:

• Hepatology
• Metabolic Disorders
• Internal Medicine

Background:

• Nonalcoholic fatty liver disease (NAFLD) has been renamed metabolic-associated fatty liver disease (MAFLD).
• Understanding MAFLD subtypes, particularly lean MAFLD, is crucial following the nomenclature change.
• Previous evidence on lean NAFLD requires re-evaluation for its relevance to MAFLD.

Purpose of the Study:

• To examine recent data on lean MAFLD cohorts.
• To highlight the prevalence, characteristics, and complications of lean MAFLD.
• To review the prognosis, treatment, and ongoing research for lean MAFLD.

Main Methods:

• Review of recently published data on lean MAFLD cohorts.
• Analysis of epidemiological, clinical, and genetic factors.
• Evaluation of hepatic and extrahepatic complications and prognosis.

Main Results:

• Prevalence and specific pathophysiological characteristics of lean MAFLD are being defined.
• Association with liver fibrosis, genetic factors, and distinct complications are under investigation.
• Prognosis and treatment strategies for lean MAFLD are emerging areas of research.

Conclusions:

• Lean MAFLD represents a unique subtype requiring dedicated study.
• Further research is needed to fully elucidate the clinical spectrum and management of lean MAFLD.
• The transition from NAFLD to MAFLD necessitates updated understanding of lean patient populations.